SOUTH SAN FRANCISCO, Calif., July 26, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been...
SOUTH SAN FRANCISCO, Sept. 30, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
SOUTH SAN FRANCISCO, Calif., June 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
– Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck SOUTH SAN FRANCISCO, Calif., April 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
SOUTH SAN FRANCISCO, Calif., August 25, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and...
Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate technologies and to expand its oncology pipeline Sutro’s Xpress CF+™ platforms to be utilized to develop...
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with...
CARLOS V. PAYA, M.D., Ph.D. Chair, Scientific Advisory Board Carlos Paya, M.D., Ph.D. is currently the Senior Advisor at Abingworth Ventures, Chair, Board of Directors at Fluidigm and Highlight Therapeutics since 2020 and Board member at BIO, Fluidigm and...
